OPG (osteoprotegerin) has been suggested to have an important role in atherogenesis and vascular calcification. In the present study, we have investigated serum OPG and RANKL (receptor activator of nuclear factor κB ligand) concentrations in patients with ST elevation AMI (acute myocardial infarction) and established CAD (coronary artery disease). OPG and RANKL were measured in 58 male patients hospitalized in the coronary care unit with ST elevation AMI, in 52 asymptomatic male patients with an established diagnosis of CAD and in 52 healthy male controls. These last two groups were matched with the AMI patients for age and body mass index. OPG was significantly (P<0.05) higher in patients with AMI at 1 h after AMI (8.04±4.86 pmol/l) than in both patients with established CAD (4.92±1.65 pmol/l) and healthy subjects (3.15±1.01 pmol/l). Subjects with established CAD had significantly (P<0.05) increased OPG levels compared with controls. RANKL levels in patients with established CAD (0.02±0.05 pmol/l) and with AMI (0.11±0.4 pmol/l) were significantly (P<0.05) lower compared with controls (0.32±0.35 pmol/l). In the AMI group, OPG decreased significantly (P<0.05) at 1 and 4 weeks after infarction (8.04±4.86 compared with 6.38±3.87 and 6.55±2.6 pmol/l respectively), but OPG levels, either at 1 h or 1–4 weeks after AMI, remained significantly (P<0.05) higher compared with established CAD (4.92±1.65 pmol/l) and controls (3.15±1.01 pmol/l). Our data show for the first time that OPG levels are increased in ST elevation AMI within 1 h of infarction. Whether the increase in OPG is a consequence or a causal factor of plaque destabilization deserves further investigation.
Skip Nav Destination
Article navigation
October 2005
-
Cover Image
Cover Image
- PDF Icon PDF LinkTable of Contents
Research Article|
September 23 2005
Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction
Alessandra Crisafulli;
*Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Sicily, Italy
†Section of Pharmacology, Department of Biomedical Sciences, University of Modena and Reggio Emilia, Italy
Correspondence: Dr Alessandra Crisafulli, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Italy (email [email protected]).
Search for other works by this author on:
Antonio Micari;
Antonio Micari
*Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Sicily, Italy
Search for other works by this author on:
Domenica Altavilla;
Domenica Altavilla
*Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Sicily, Italy
Search for other works by this author on:
Francesco Saporito;
Francesco Saporito
*Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Sicily, Italy
Search for other works by this author on:
Aurora Sardella;
Aurora Sardella
*Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Sicily, Italy
Search for other works by this author on:
Maria Passaniti;
Maria Passaniti
*Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Sicily, Italy
Search for other works by this author on:
Santi Raffa;
Santi Raffa
*Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Sicily, Italy
Search for other works by this author on:
Gaspare D'Anneo;
Gaspare D'Anneo
‡Department of Internal Medicine, Azienda Ospedaliera Papardo, Messina, Sicily, Italy
Search for other works by this author on:
Fabiana Lucà;
Fabiana Lucà
*Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Sicily, Italy
Search for other works by this author on:
Chiara Mioni;
Chiara Mioni
*Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Sicily, Italy
Search for other works by this author on:
Francesco Arrigo;
Francesco Arrigo
*Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Sicily, Italy
Search for other works by this author on:
Francesco Squadrito
Francesco Squadrito
*Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Sicily, Italy
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
February 10 2005
Revision Received:
May 27 2005
Accepted:
May 31 2005
Accepted Manuscript online:
May 31 2005
Online ISSN: 1470-8736
Print ISSN: 0143-5221
The Biochemical Society
2005
Clin Sci (Lond) (2005) 109 (4): 389–395.
Article history
Received:
February 10 2005
Revision Received:
May 27 2005
Accepted:
May 31 2005
Accepted Manuscript online:
May 31 2005
Citation
Alessandra Crisafulli, Antonio Micari, Domenica Altavilla, Francesco Saporito, Aurora Sardella, Maria Passaniti, Santi Raffa, Gaspare D'Anneo, Fabiana Lucà, Chiara Mioni, Francesco Arrigo, Francesco Squadrito; Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond) 1 October 2005; 109 (4): 389–395. doi: https://doi.org/10.1042/CS20050058
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |